Jeremy Bahr appointed Chief Business Officer

Published: 5 May 2017Organisational Announcements

Oslo, Norway, May 5 2017: Photocure ASA (OSE:PHO), today announced the appointment of Jeremy Bahr as Chief Business Officer.

"I am pleased to welcome Jeremy to the Photocure team, strengthening our strategic, commercial and transactional capabilities, where he will lead our business development activities and strategic initiatives within marketing and market access. Jeremy joins Photocure as Chief Business Officer with over 20 years of professional experience and I look forward to working with him as a member of the Photocure management team," says Kjetil Hestdal, President and Chief Executive Officer of Photocure.

Bahr comes from UCB, where his most recent role was Global Head of Market Analytics at UCB, and where he also previously served as Head of Commercial Operations in North America. Prior to UCB, he spent 7 years at Pfizer where he held senior roles within strategy, sales and marketing. Earlier in his career he worked in private equity, as an entrepreneur and spent several years as a consultant at McKinsey & Company.

Jeremy Bahr holds an MBA from Harvard Business School, and bachelor's degrees in Molecular Biology and Political Science from Brigham Young University.

For further information, please contact:

Kjetil Hestdal
President & CEO
Tel: + 47 913 19 535

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000

Notes to editors

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company focusing on urology. Based on its unique proprietary Photocure Technology® platform, Photocure is committed to developing and commercializing highly selective and minimally invasive solutions to improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

News and events